Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ctDNA-guided Adaptive Therapy Escalation in ER+ MBC: A Phase 1b Study With Letrozole, Palbociclib and Onapristone ER

Next Previous
X
Search
Trial Profile

ctDNA-guided Adaptive Therapy Escalation in ER+ MBC: A Phase 1b Study With Letrozole, Palbociclib and Onapristone ER

Status: Withdrawn prior to enrolment
Phase of Trial: Phase I/II

Latest Information Update: 02 May 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Onapristone (Primary) ; Letrozole; Palbociclib
  • Indications Advanced breast cancer
  • Focus Adverse reactions

    • Most Recent Events

    • 26 Apr 2023 Status changed from recruiting to withdrawn prior to enrolment. The sponsor closed the study due to discontinuing their onapristone program.
    • 10 Dec 2022 Trial design presented at the 45th Annual San Antonio Breast Cancer Symposium
    • 11 Aug 2022 According to a Context Therapeutics media release, enrollment continues primarily due to slower than anticipated patient enrollment and preliminary data from the Phase 1b portion of the trial is expected in mid 2023.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top